XML 50 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting  
Schedule of information about the Company's single segment

Three Months Ended March 31, 

2025

    

2024

Revenue

$

10,698

$

14,774

Cost of product revenue

1,262

1,326

Research and development (a)

Direct program expenses

AXPAXLI for wet AMD

24,455

5,493

Other clinical and preclinical programs

1,081

3,215

Unallocated expenses

Personnel costs

8,983

7,128

All other costs

3,255

802

Selling and marketing (a)

12,817

9,262

General and administrative (a)

9,661

8,344

Facilities (b)

1,664

1,923

Stock-based compensation

10,456

7,978

Depreciation

981

920

Interest income

3,826

3,922

Interest expense

(2,984)

(4,051)

Loss from debt extinguishment

(27,950)

Other non-operating items

(978)

(5,152)

Net loss

$

(64,053)

$

(64,848)

(a)excluding stock-based compensation, depreciation, and facilities expenses
(b)excluding stock-based compensation and depreciation